CLASS ACTION UPDATE for PCG, FLKS and RMTI: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
Levi & Korsinsky, LLP
Jul. 31, 2018
NEW YORK, July 31, 2018 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court and further details about the cases can be found at the links provided. There is no cost or obligation to you.
PG&E Corporation (NYSE: PCG) Class Period: April 29, 2015 - June 8, 2018 Lead Plaintiff Deadline: August 13, 2018 Join the action: http://www.zlk.com/pslra-d/pge-corporation?wire=3
About the lawsuit: PG&E Corporation allegedly made materially false and/or misleading statements during the class period and/or failed to disclose that: (i) PG&E had failed to maintain electricity transmission and distribution networks in compliance with safety requirements and regulations promulgated under state law; (ii) consequently, PG&E was in violation of state law regulation; (iii) PG&E’s electricity networks would cause numerous wildfires in California; and (iv) as a result of the foregoing, Defendants’ statements about the Company’s business and operations were materially false and misleading at all relevant times.
To learn more about the PCG class action contact firstname.lastname@example.org.
Flex Pharma, Inc. (NASDAQ: FLKS) Class Period: November 6, 2017 - June 12, 2018 Lead Plaintiff Deadline: August 20, 2018 Join the action: http://www.zlk.com/pslra-d/flex-pharma-inc?wire=3
About the lawsuit: During the class period, Flex Pharma, Inc. allegedly made materially false and/or misleading statements and/or failed to disclose that: (i) the Company overstated the viability and approval prospects for its product candidate FLX-787 for the treatment of amyotrophic lateral sclerosis and Charcot-Marie-Tooth disease; and (ii) as a result, Flex's public statements were materially false and misleading at all relevant times.
On June 13, 2018, Flex announced that it planned to halt its FLX-787 trials, citing oral tolerability concerns observed in both studies. Flex also said that it will restructure its organization to reduce costs, including reducing its workforce by approximately 60%, and that Flex's Board is exploring "strategic alternatives, including the potential sale or merger of the company." Following this news, Flex stock dropped $3.14 per share, or 75.12%, to close at $1.04 on June 13, 2018.
To learn more about the FLKS class action contact email@example.com.
Rockwell Medical, Inc. (NASDAQ: RMTI) Class Period: March 16, 2018 - June 26, 2018 Lead Plaintiff Deadline: September 25, 2018 Join the action: http://www.zlk.com/pslra-d/rockwell-medical-inc?wire=3
About the lawsuit: Throughout the class period, Rockwell Medical, Inc. allegedly made materially false and/or misleading statements and/or failed to disclose that: (1) Rockwell was aware that The Centers for Medicare and Medicaid Services will not pursue Rockwell’s proposal for separate reimbursement for the drug Triferic; (2) the estimated reserves in the first quarter 2018 10-Q are misstated; (3) there was a material weakness in Rockwell’s internal controls over financial reporting; (4) consequently, Rockwell’s internal controls over financial reporting were ineffective during the Class Period; (5) Defendant Chioini withheld material information regarding Triferic from Rockwell’s auditor, corporate counsel and five independent directors of the Board; and (6) as a result, Defendants’ statements about the Company’s business, operations and prospects were materially false and misleading and/or lacked reasonable bases at all relevant times.
To learn more about the RMTI class action contact firstname.lastname@example.org.
You have until the lead plaintiff deadlines to request the court appoint as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. Levi & Korsinsky is a national firm with offices in New York, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.CONTACT:Levi & Korsinsky, LLPJoseph E. Levi, Esq.30 Broad Street - 24th FloorNew York, NY 10004 email@example.com Tel: (212) 363-7500Toll Free: (877) 363-5972Fax: (212) 363-7171www.zlk.com